Benzinga | Dec 15, 2020 06:35AM EST

Citigroup Downgrades Alexion Pharmaceuticals to Neutral, Announces $175 Price Target

Citigroup analyst Mohit Bansal downgrades Alexion Pharmaceuticals (NASDAQ:ALXN) from Buy to Neutral and announces $175 price target.